RA Cap­i­tal backs Ox­ford spin­out Pep­Gen with a $45M Se­ries A, seek­ing to treat Duchenne and oth­er sim­i­lar dis­eases

Less than two months af­ter Pe­ter Kolchin­sky and Raj Shah an­nounced a new $461 mil­lion fund, the part­ners at RA Cap­i­tal Man­age­ment ap­pear to have made an­oth­er in­vest­ment.

RA is head­lin­ing a $45 mil­lion Se­ries A round for the Ox­ford, UK-based biotech Pep­Gen, which fo­cus­es on se­vere neu­ro­mus­cu­lar dis­eases like Duchenne mus­cu­lar dy­s­tro­phy. The com­pa­ny will use the fund­ing to ad­vance a slate of what they’re call­ing “cell-pen­e­trat­ing” pep­tides — com­bined with some of their pro­pri­etary con­ju­gates — in­to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER